Overview: Canavan Disease Marker TestIntroduction: The Canavan Disease Marker Test tests for elevated N-acetylaspartic acid to diagnose Canavan disease, a rare neurological disorder causing developmental delays and seizures, aiding early diagnosis. Affecting 1 in 100,000 newborns, this disorder poses diagnostic challenges due to its progressive nature. Following 2023 National Organization for Rare Disorders (NORD) guidelines, it uses GC-MS for high accuracy, supporting biochemistry screening. This test is essential for diagnosis, genetic counseling, and improving outcomes in pediatrics.
Other Names: N-acetylaspartic Acid Test, Canavan Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic reliability.
Historical Milestone: Metabolic marker testing began in the 1980s with research by Matalon, who identified N-acetylaspartic acid in Canavan disease. GC-MS advancements in the 2000s by companies like Agilent improved detection, surpassing earlier HPLC methods.
Purpose: Measures N-acetylaspartic acid levels to diagnose Canavan disease, guides supportive therapy, and evaluates children with developmental delays, aiming to manage symptoms.
Test Parameters: N-acetylaspartic acid levels
Pretest Condition: No special preparation required. Collect urine or plasma. Report history of developmental issues.
Specimen: Urine (sterile container, 5-20 mL), Plasma (NaHep, 2-4 mL); 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: 1 month
Medical History: Document developmental delay or seizures. Include current medications or family history of neurological disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., disability), and sample collection risks.
Procedural Considerations: Uses GC-MS to measure N-acetylaspartic acid, requiring labs with mass spectrometers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Elevated levels confirm Canavan disease, guiding supportive care. Early diagnosis might slow progression, while untreated cases lead to death. Normal levels may require MRI.
Specialist Consultation: Consult a pediatrician or genetic counselor for interpretation.
Additional Supporting Tests: MRI, urine organic acids, or genetic testing to confirm diagnosis.
Test Limitations: Specific to Canavan; correlation with symptoms needed. False negatives possible with sample issues.
References: NORD Guidelines, 2023; Journal of Pediatrics, Matalon R, 2022.
